PARP inhibitors are currently explored in the ongoing trials also in prostate cancer in the combination with drugs targeting cell signaling pathways, such as an AKT inhibitor ipatasertib, and a VEGFR inhibitor cediranib. The gene discussed is PARP1; the disease is prostate carcinoma.